

Singapore approves world's first respiratory syncytial virus vaccine for older adults

16 May 2024 | News

Arexvy is the first RSV vaccine approved in Singapore

GSK's Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

The first respiratory syncytial virus (RSV) vaccine in the world and the first RSV vaccine approved in the country, Arexvy (recombinant, AS01E adjuvanted) further strengthens the company's portfolio of vaccines aimed to protect older adults in Singapore from a variety of infectious diseases.

In a four-year study in Singapore, one out of every 20 older adults aged 65 years or over has tested positive for RSV. It is a common, contagious virus that affects the lungs and respiratory airways.

"People aged 60 years or over could be our parents, grandparents, uncles or aunts, whom we live with at home - and they could be exposed to RSV. By 2030, one in four Singaporeans are expected to be over 65 years of age. This indicates a large cohort who could be at risk for RSV. The downstream costs and burden on the healthcare system and economy will further increase as the population ages," said Dr Stephanie Cinthu Stephen Ambrose, Country Medical Director, GSK Singapore.

GSK's RSV older adult vaccine contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01E adjuvant. In Singapore, Arexvy is indicated to protect against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and over. The vaccine has also been approved for the prevention of RSV-LRTD in individuals 60 years of age and older in Europe, Japan, UK, Canada, Australia, Hong Kong, Taiwan and several other countries and regions. Regulatory reviews in multiple countries are ongoing.